1. Nikezić AVV, Bondžić AM, Vasić VM. Drug delivery systems based on nanoparticles and related nanostructures. Eur J Pharm Sci. 2020;151:105412. doi:https://doi.org/10.1016/j.ejps.2020.105412.
2. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. J Cancer research. 2008;68(12):4774-82. doi:https://doi.org/10.1158/0008-5472.CAN-07-6307.
3. Wind S, Schmid U, Freiwald M, Marzin K, Lotz R, Ebner T et al. Clinical pharmacokinetics and pharmacodynamics of nintedanib. J Clinical pharmacokinetics. 2019;58(9):1131-47. doi:https://doi.org/10.1007/s40262-019-00766-0.
4. Tepede A, Yogaratnam D. Nintedanib for idiopathic pulmonary fibrosis. J Pharm Pract. 2019;32(2):199-206. doi:https://doi.org/10.1177/0897190017735242.
5. Zhu Y, Fu Y, Zhang A, Wang X, Zhao Z, Zhang Y et al. Rod-shaped nintedanib nanocrystals improved oral bioavailability through multiple intestinal absorption pathways. Eur J Pharm Sci. 2021:106047. doi:https://doi.org/10.1016/j.ejps.2021.106047.
6. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717. doi:https://doi.org/10.1038/srep42717.
7. Pillai O, Dhanikula AB, Panchagnula R. Drug delivery: An odyssey of 100 years. Curr Opin Chem Biol. 2001;5(4):439-46. doi:https://doi.org/10.1016/s1367-5931(00)00226-x.
8. Mandal SC, Mandal M. Current status and future prospects of new drug delivery system. J Pharm Times. 2010;42(4):13-6.
9. El-Hammadi MM, Arias JL. An update on liposomes in drug delivery: a patent review (2014-2018). Expert Opin Ther Pat. 2019;29(11):891-907. doi:https://doi.org/10.1080/13543776.2019.1679767.
10. Kraft JC, Freeling JP, Wang Z, Ho RJ. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci. 2014;103(1):29-52. doi:https://doi.org/10.1002/jps.23773.
11. Patel P, Patel M. Enhanced oral bioavailability of nintedanib esylate with nanostructured lipid carriers by lymphatic targeting: In vitro, cell line and in vivo evaluation. Eur J Pharm Sci. 2021;159:105715. doi:https://doi.org/10.1016/j.ejps.2021.105715.
12. Velagacherla V, Suresh A, Mehta CH, Nayak UY. Advances and challenges in nintedanib drug delivery. Expert opinion on drug delivery. 2021;18(11):1687-706. doi:https://doi.org/10.1080/17425247.2021.1985460.
13. Epstein-Shochet G, Pham S, Beck S, Naiel S, Mekhael O, Revill S et al. Inhalation: A means to explore and optimize nintedanib's pharmacokinetic/pharmacodynamic relationship. Pulmonary pharmacology therapeutics and Clinical Risk Management. 2020;63:101933. doi:https://doi.org/10.1016/j.pupt.2020.101933.
14. Dallinger C, Trommeshauser D, Marzin K, Liesener A, Kaiser R, Stopfer P. Pharmacokinetic properties of nintedanib in healthy volunteers and patients with advanced cancer. The Journal of Clinical Pharmacology. 2016;56(11):1387-94. doi:https://doi.org/10.1002/jcph.752.
15. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29(3-4):278-87. doi:https://doi.org/10.1016/j.ejps.2006.04.016.
16. Sharma P, Garg S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv Drug Deliv Rev. 2010;62(4-5):491-502. doi:https://doi.org/10.1016/j.addr.2009.11.019.
17. Kala SG, Chinni S. Development of Raloxifene Hydrochloride Loaded mPEG-PLA Nanoparticles for Oral Delivery. Indian Journal of Pharmaceutical Education Research. 2021;55(1):S135-S48. doi:https://doi.org/10.5530/ijper.55.1s.44.
18. Kala SG, Chinni S. Development and Characterization of Venetoclax Nanocrystals for Oral Bioavailability Enhancement. AAPS PharmSciTech. 2021;22(3):1-11. doi:https://doi.org/10.1208/s12249-021-01968-1.
19. Kuai Q, Wang Y, Gao F, Qi Y, Wang R, Wang Y et al. Peptide self-assembly nanoparticles loaded with panobinostat to activate latent human immunodeficiency virus. J Biomed Nanotechnol. 2019;15(5):979-92. doi:https://doi.org/10.1166/jbn.2019.2764.
20. Singleton W, Collins A, Bienemann A, Killick-Cole C, Haynes H, Asby D et al. Convection enhanced delivery of panobinostat (LBH589)-loaded pluronic nano-micelles prolongs survival in the F98 rat glioma model. International journal of nanomedicine. 2017;12:1385. doi:https://doi.org/10.2147/IJN.S125300.
21. Jose G, Lu Y-J, Hung J-T, Yu AL, Chen J-P. Co-Delivery of CPT-11 and Panobinostat with Anti-GD2 Antibody Conjugated Immunoliposomes for Targeted Combination Chemotherapy. Cancers (Basel). 2020;12(11):3211. doi:https://doi.org/10.3390/cancers12113211.
22. Fu Y, Saraswat A, Wei Z, Agrawal MY, Dukhande VV, Reznik SE et al. Development of Dual ARV-825 and Nintedanib-Loaded PEGylated Nano-Liposomes for Synergistic Efficacy in Vemurafnib-Resistant Melanoma. Pharmaceutics. 2021;13(7):1005. doi:https://doi.org/10.3390/pharmaceutics13071005.
23. Cavaco MC, Pereira C, Kreutzer B, Gouveia LF, Silva-Lima B, Brito AM et al. Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles. European Journal of Pharmaceutics. 2017;110:76-84. doi:https://doi.org/10.1016/j.ejpb.2016.10.024.
24. Gabizon AA, Shmeeda H, Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. Journal of liposome research. 2006;16(3):175-83. doi:https://doi.org/10.1080/08982100600848769.
25. Felice B, Prabhakaran MP, Rodriguez AP, Ramakrishna S. Drug delivery vehicles on a nano-engineering perspective. Materials Science Engineering: C. 2014;41:178-95. doi:https://doi.org/10.1016/j.msec.2014.04.049.
26. Cipolla D, Wu H, Salentinig S, Boyd B, Rades T, Vanhecke D et al. Formation of drug nanocrystals under nanoconfinement afforded by liposomes. RSC advances. 2016;6(8):6223-33. doi:https://doi.org/10.1039/C5RA25898G.
27. Zhang Z, Tan S, Feng S-S. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials. 2012;33(19):4889-906. doi:https://doi.org/10.1016/j.biomaterials.2012.03.046.
28. Li N, Mai Y, Liu Q, Gou G, Yang J. Docetaxel-loaded D-α-tocopheryl polyethylene glycol-1000 succinate liposomes improve lung cancer chemotherapy and reverse multidrug resistance. Drug Delivery translational Research: The Journal of Laboratory and Clinical Medicine. 2021;11(1):131-41. doi:https://doi.org/10.1007/s13346-020-00720-9.
29. Parmar YB, Shah D, Majmudar YA, Kaka KC, Patel AS, Kankad PD et al. The novel analytical method development and validation for related substances of nintedanib esylate by RP-HPLC method. World Journal of Pharmaceutical Research. 2020;10(1):131-54. doi:https://doi.org/10.20959/wjpr20211-18950.
30. Waghmare SA, Sumithra M. QbD Based Development and Validation of RP-HPLC Method for Nintedanib Esylate: Application to Bioanalytical and Stability Study in Plasma. Analytical Chemistry Letters. 2021;11(3):392-408. doi:https://doi.org/10.1080/22297928.2021.1930581.
31. Pasquini B, Orlandini S, Furlanetto S, Gotti R, Del Bubba M, Boscaro F et al. Quality by Design as a risk-based strategy in pharmaceutical analysis: Development of a liquid chromatography-tandem mass spectrometry method for the determination of nintedanib and its impurities. J Chromatogr A. 2020;1611:460615. doi:https://doi.org/10.1016/j.chroma.2019.460615.
32. Jain S, Kumar D, Swarnakar NK, Thanki K. Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. Biomaterials. 2012;33(28):6758-68. doi:https://doi.org/10.1016/j.biomaterials.2012.05.026.
33. Jain S, Deore SV, Ghadi R, Chaudhari D, Kuche K, Katiyar SS. Tumor microenvironment responsive VEGF-antibody functionalized pH sensitive liposomes of docetaxel for augmented breast cancer therapy. Materials Science Engineering: C. 2021;121:111832. doi:https://doi.org/10.1016/j.msec.2020.111832.
34. Tsumoto K, Matsuo H, Tomita M, Yoshimura T. Efficient formation of giant liposomes through the gentle hydration of phosphatidylcholine films doped with sugar. Colloids Surfaces B: Biointerfaces. 2009;68(1):98-105. doi:https://doi.org/10.1016/j.colsurfb.2008.09.023.
35. Maxwell SE, Delaney HD, Kelley K. Designing experiments and analyzing data: A model comparison perspective. Routledge; 2017.
36. Kala SG, Chinni S. Solid State Characterization of Olmesartan medoximil Solid Dispersion and in-silico Formulation Design using Quality by Design Techniques Engendered by Definitive Screening Design. J Young Pharm. 2021;13(1). doi:https://doi.org/10.5530/jyp.2021.13.11.
37. Jones B, Nachtsheim CJ. A class of three-level designs for definitive screening in the presence of second-order effects. J Food Qual Technol. 2011;43(1):1-15. doi:https://doi.org/10.1080/00224065.2011.11917841.
38. Lawrence XY. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res. 2008;25(4):781-91. doi:https://doi.org/10.1007/s11095-007-9511-1.
39. Pellequer Y, Ollivon M, Barratt G. Formulation of liposomes associated with recombinant interleukin-2: effect on interleukin-2 activity. Biomed Pharmacother. 2004;58(3):162-7. doi:https://doi.org/10.1016/j.biopha.2003.12.008.
40. Lopez-Pinto J, Gonzalez-Rodriguez M, Rabasco A. Effect of cholesterol and ethanol on dermal delivery from DPPC liposomes. Int J Pharm. 2005;298(1):1-12. doi:https://doi.org/10.1016/j.ijpharm.2005.02.021.
41. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Advanced drug delivery reviews. 2006;58(15):1688-713. doi:https://doi.org/10.1016/j.addr.2006.09.017.
42. Bapat P, Ghadi R, Chaudhari D, Katiyar SS, Jain S. Tocophersolan stabilized lipid nanocapsules with high drug loading to improve the permeability and oral bioavailability of curcumin. Int J Pharm. 2019;560:219-27. doi:https://doi.org/10.1016/j.ijpharm.2019.02.013.
43. Cho YW, Lee J, Lee SC, Huh KM, Park K. Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles. J Control Release. 2004;97(2):249-57. doi:https://doi.org/10.1016/j.jconrel.2004.03.013.
44. Kalaria D, Sharma G, Beniwal V, Kumar MR. Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res. 2009;26(3):492-501. doi:https://doi.org/10.1007/s11095-008-9763-4.
45. Upadhyay KK, Bhatt AN, Mishra AK, Dwarakanath BS, Jain S, Schatz C et al. The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly (γ-benzyl l-glutamate)-b-hyaluronan polymersomes. Biomaterials. 2010;31(10):2882-92. doi:https://doi.org/10.1016/j.biomaterials.2009.12.043.
46. Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C et al. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. The AAPS journal. 2010;12(3):263-71. doi:https://doi.org/10.1208/s12248-010-9185-1.
47. Vertzoni M, Fotaki N, Nicolaides E, Reppas C, Kostewicz E, Stippler E et al. Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects. Journal of pharmacy and pharmacology & Therapeutics Part B: General and Systematic Pharmacology. 2004;56(4):453-62. doi:https://doi.org/10.1211/0022357022935.
48. Crosasso P, Ceruti M, Brusa P, Arpicco S, Dosio F, Cattel L. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J Control Release. 2000;63(1-2):19-30. doi:https://doi.org/10.1016/S0168-3659(99)00166-2.
49. Zimmermann E, Müller RH. Electrolyte-and pH-stabilities of aqueous solid lipid nanoparticle (SLN™) dispersions in artificial gastrointestinal media. European Journal of Pharmaceutics Biopharmaceutics and Drug Disposition. 2001;52(2):203-10. doi:https://doi.org/10.1016/S0939-6411(01)00167-9.
50. Yang T, Cui F-D, Choi M-K, Cho J-W, Chung S-J, Shim C-K et al. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm. 2007;338(1-2):317-26. doi:https://doi.org/10.1016/j.ijpharm.2007.02.011.
51. Jain AK, Swarnakar NK, Godugu C, Singh RP, Jain S. The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials. 2011;32(2):503-15. doi:https://doi.org/10.1016/j.biomaterials.2010.09.037.
52. Choi B-C, Choi J-S, Han H-K. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats. Int J Pharm. 2006;323(1-2):81-5. doi:https://doi.org/10.1016/j.ijpharm.2006.05.046.
53. Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99(3):306-14. doi:https://doi.org/10.1016/j.cmpb.2010.01.007.
54. Socaciu C, Jessel R, Diehl HA. Competitive carotenoid and cholesterol incorporation into liposomes: effects on membrane phase transition, fluidity, polarity and anisotropy. Chem Phys Lipids. 2000;106(1):79-88. doi:https://doi.org/10.1016/S0009-3084(00)00135-3.
55. Chou T-H, Chu I-M, Chang C-H. Interaction of paclitaxel with DSPC in monolayers at the air/water interface at different temperatures. Colloids Surfaces B: Biointerfaces. 2002;25(2):147-55. doi:https://doi.org/10.1016/S0927-7765(01)00303-4.
56. Muthu MS, Kulkarni SA, Xiong J, Feng S-S. Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells. Int J Pharm. 2011;421(2):332-40. doi:https://doi.org/10.1016/j.ijpharm.2011.09.045.
57. Jain P, Jain S, Prasad K, Jain S, Vyas SP. Polyelectrolyte coated multilayered liposomes (nanocapsules) for the treatment of Helicobacter pylori infection. Mol Pharm. 2009;6(2):593-603. doi:https://doi.org/10.1021/mp8002539.
58. Nogueira E, Gomes AC, Preto A, Cavaco-Paulo A. Design of liposomal formulations for cell targeting. Colloids surfaces B: Biointerfaces. 2015;136:514-26. doi:https://doi.org/10.1016/j.colsurfb.2015.09.034.
59. Li J, Cheng X, Chen Y, He W, Ni L, Xiong P et al. Vitamin E TPGS modified liposomes enhance cellular uptake and targeted delivery of luteolin: An in vivo/in vitro evaluation. Int J Pharm. 2016;512(1):262-72. doi:https://doi.org/10.1016/j.ijpharm.2016.08.037.
60. Yaghoobian M, Haeri A, Bolourchian N, Shahhosseni S, Dadashzadeh S. The impact of surfactant composition and surface charge of niosomes on the oral absorption of repaglinide as a BCS II model drug. International Journal of Nanomedicine. 2020;15:8767. doi:https://doi.org/10.2147/IJN.S261932.
61. Jash A, Ubeyitogullari A, Rizvi SS. Liposomes for oral delivery of protein and peptide-based therapeutics: challenges, formulation strategies, and advances. Journal of Materials Chemistry B. 2021. doi:https://doi.org/10.1039/D1TB00126D.